UBS Group’s Juniper Pharmaceuticals JNP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
– Sell
-660
Closed -$6K – 8575
2018
Q2
$6K Buy
660
+415
+169% +$3.73K ﹤0.01% 7443
2018
Q1
$2K Sell
245
-3,450
-93% -$29K ﹤0.01% 7600
2017
Q4
$18K Buy
3,695
+3,570
+2,856% +$17.4K ﹤0.01% 6650
2017
Q3
$1K Sell
125
-2,058
-94% -$9.7K ﹤0.01% 7645
2017
Q2
$11K Buy
2,183
+2,040
+1,427% +$9.13K ﹤0.01% 6747
2017
Q1
$1K Sell
143
-3,791
-96% -$19.2K ﹤0.01% 7528
2016
Q4
$22K Sell
3,934
-695
-15% -$3.82K ﹤0.01% 6470
2016
Q3
$25K Buy
4,629
+1,129
+32% +$7.47K ﹤0.01% 6122
2016
Q2
$25K Hold
3,500
– – ﹤0.01% 6131
2016
Q1
$23K Sell
3,500
-7,948
-69% -$58.5K ﹤0.01% 6110
2015
Q4
$118K Buy
11,448
+4,733
+70% +$54.9K ﹤0.01% 5084
2015
Q3
$79K Sell
6,715
-1,486
-18% -$16.4K ﹤0.01% 5428
2015
Q2
$75K Buy
8,201
+2,987
+57% +$22.6K ﹤0.01% 5646
2015
Q1
$33K Buy
5,214
+134
+3% +$829 ﹤0.01% 6469
2014
Q4
$28K Hold
5,080
– – ﹤0.01% 7200
2014
Q3
$30K Sell
5,080
-1,572
-24% -$9.6K ﹤0.01% 7487
2014
Q2
$46K Buy
6,652
+1,572
+31% +$10.5K ﹤0.01% 6993
2014
Q1
$37K Sell
5,080
-1,888
-27% -$13K ﹤0.01% 7255
2013
Q4
$46K Buy
6,968
+1,580
+29% +$10.8K ﹤0.01% 7063
2013
Q3
$39K Buy
+5,388
New +$36.3K ﹤0.01% 7194

UBS Group's JNP Position: Q3 2018 in Review

UBS Group sold out of Juniper Pharmaceuticals (JNP) in Q3 2018, closing a stake of 660 shares — an estimated $6K sold.

UBS Group first reported a position in JNP in Q3 2013 and held it in 20 quarters. The position peaked at $118K in Q4 2015. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.

  • UBS Group reported no remaining Juniper Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • UBS Group sold 660 Juniper Pharmaceuticals shares in Q3 2018, an estimated $6K.
  • UBS Group first reported a position in Juniper Pharmaceuticals in Q3 2013 and held it in 20 quarters.
  • UBS Group's Juniper Pharmaceuticals position peaked at $118K in Q4 2015.
  • 0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals as of Q3 2018.

Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.